Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on CLL (Nov 2018)

Posted by Matt Breese on Nov 2, 2018

Find me on:

According to our recent payer coverage analysis for chronic lymphocyctic leukemia (CLL) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for CLL treatments shows that more than half of the covered lives under Medicare formularies are restricted. 

MMIT-Reality Check-CLL-4Q2018Data snapshot as of Q4 2018

Trends: The FDA approved Verastem, Inc.'s Copiktra (duvelisib) for the treatment of adults with relapsed or refractory CLL after at least two treatments. 

To read the full Reality Check on Chronic Lymphocyctic Leukemia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing